×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DERM – journey medical corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DERM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/10
08:30 am
derm
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
Medium
Report
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
11/19
08:31 am
derm
What Makes Journey Medical Corporation (DERM) a Good Investment? [Yahoo! Finance]
Medium
Report
What Makes Journey Medical Corporation (DERM) a Good Investment? [Yahoo! Finance]
11/18
06:19 am
derm
Journey Medical Corp (DERM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Medium
Report
Journey Medical Corp (DERM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
11/12
10:47 pm
derm
Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
07:34 pm
derm
Journey Medical Corporation (DERM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
Journey Medical Corporation (DERM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
04:27 pm
derm
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Medium
Report
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
11/12
04:01 pm
derm
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Medium
Report
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
11/11
07:08 pm
derm
What To Expect From Journey Medical Corp (DERM) Q3 2025 Earnings [Yahoo! Finance]
Low
Report
What To Expect From Journey Medical Corp (DERM) Q3 2025 Earnings [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
04:01 pm
derm
journey medical corporation
BEAT
Report
-13.3%
journey medical corporation
8/12/2025
04:01 pm
derm
journey medical corporation
BEAT
Report
-16.6%
journey medical corporation
5/14/2025
04:01 pm
derm
journey medical corporation
BEAT
Report
18.9%
journey medical corporation
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
04:41 pm
derm
Form 10-Q Journey Medical Corp For: Sep 30
Medium
Report
Form 10-Q Journey Medical Corp For: Sep 30
11/12
04:08 pm
derm
Form 8-K Journey Medical Corp For: Nov 12
High
Report
Form 8-K Journey Medical Corp For: Nov 12
9/26
04:39 pm
derm
Form 8-K Journey Medical Corp For: Sep 25
Low
Report
Form 8-K Journey Medical Corp For: Sep 25
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/17
Dermira Presents Data From Phase 2b Study of Lebrikizumab in Patients With Atopic Dermatitis at Fall Clinical Dermatology Conference
25.8%
12/10 Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 15.2%
5/7 Dermira, Inc. (DERM) CEO Tom Wiggans on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 12.0%
12/12 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 10.6%
8/7 Q2/2019 6/30/2019 EPS -0.330 ZacksConsensus -0.900 ActVsEst 0.570 - Beat 10.6%
6/6 Form 4 Dermira, Inc. For: Jun 04 Filed by: Cohen David E 7.3%
12/10 Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis 7.2%
6/14 Form 4 Dermira, Inc. For: Jun 12 Filed by: Nunn Jason Raleigh 5.1%
8/17 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.1%
1/3 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.1%
12/10 Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 15.2%
5/7 Dermira, Inc. (DERM) CEO Tom Wiggans on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 12.0%
12/12 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 10.6%
8/7 Q2/2019 6/30/2019 EPS -0.330 ZacksConsensus -0.900 ActVsEst 0.570 - Beat 10.6%
6/6 Form 4 Dermira, Inc. For: Jun 04 Filed by: Cohen David E 7.3%
12/10 Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis 7.2%
6/14 Form 4 Dermira, Inc. For: Jun 12 Filed by: Nunn Jason Raleigh 5.1%
8/17 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.1%
1/3 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.1%
TOP News Decliners
11/5
Form 10-Q Dermira, Inc. For: Sep 30
-9.1%
11/13 Dermira Elects Halley E. Gilbert to its Board of Directors -6.9%
6/10 Form 8-K Dermira, Inc. For: Jun 04 -6.1%
11/5 Dermira Inc (NASDAQ: DERM) had its "outperform" rating re-affirmed by analysts at Leerink Swann. They now have a $15.00 price target on the stock, down previously from $23.00. -5.6%
5/8 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.3%
10/12 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -5.2%
8/7 Form 8-K Dermira, Inc. For: Aug 07 -5.0%
5/14 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.5%
8/9 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -4.4%
10/9 Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis -4.1%
11/13 Dermira Elects Halley E. Gilbert to its Board of Directors -6.9%
6/10 Form 8-K Dermira, Inc. For: Jun 04 -6.1%
11/5 Dermira Inc (NASDAQ: DERM) had its "outperform" rating re-affirmed by analysts at Leerink Swann. They now have a $15.00 price target on the stock, down previously from $23.00. -5.6%
5/8 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.3%
10/12 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -5.2%
8/7 Form 8-K Dermira, Inc. For: Aug 07 -5.0%
5/14 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.5%
8/9 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -4.4%
10/9 Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis -4.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: